BRAINXPLORE

Explore our scientific resources

Get our newsletters

Published on the 22 May 2022

The Anxiolytic-like Properties of a Tryptic Hydrolysate of Bovine αs1 Casein Containing α-Casozepine Rely on GABAA Receptor Benzodiazepine Binding Sites but Not the Vagus Nerve

Background A tryptic hydrolysate of bovine αs1-casein (CH) exerts anxiolytic-like properties in many species, including humans. This is mainly related to the presence of α-casozepine (α-CZP), which…

Publications
Published on the 22 September 2021

Newsletter #11: World Alzheimer’s Day: review of the ETAP-Lab preclinical models

We'd like to take the opportunity, on World Alzheimer's Day, to revisit the models ETAP-Lab makes available to the scientific community for use in the search for new therapies to fight this disease. …

Technical notes
Published on the 21 May 2021

Newsletter #9 : ETAP-Lab launches its new model, associating beta-amyloid oligomers and aged mice

In May 2021, ETAP-Lab is adding its latest mouse model of Alzheimer’s disease to its catalogue. Using our expertise in the manufacture of oligomers from A-beta1-42 peptide, we have demonstr…

Technical notes
Published on the 27 November 2020

New hope for Alzheimer’s disease: what’s combining therapeutic strategies all about?

Evidence from various studies indicates that Alzheimer’s Disease (AD) develops as a result of interaction between multiple complex and overlapping pathophysiological pathways, suggesting that a pharma…

Technical notes
Published on the 26 November 2020

Tau Clinical Trials – What can be learned from failure?

On the basis of the amyloid hypothesis of Alzheimer’s Disease (AD), most of the clinical trials conducted have concerned Aβ clearing therapy. Because of multiple failures in anti-amyloid clinical drug…

Technical notes
Published on the 26 November 2020

6 reasons to include tau oligomers in your R&D strategy for the treatment of Alzheimer’s Disease

As its name suggests, the microtubule-associated protein tau is known mainly for its role in stabilising the microtubules, thus contributing to maintenance of the axonal transport mechanisms essential…

Technical notes
Published on the 26 November 2020

Tau oligomers: a new tool for drug discovery in AD

One common pathological hallmark of neurodegenerative disease (ND) is the aggregation and accumulation of misfolding proteins, resulting in neuronal dysfunction and brain damage. A growing body of lit…

Technical notes
Published on the 25 June 2019

ETAP-Cell: a new in vitro pharmacology service for drug research in neurodegenerative diseases – Newsletter #5

The ETAP-Cell project continues to make progress as per the expected timeline. The whole team is delighted to announce that the in vitro laboratory is now fully equipped and already producing its firs…

Technical notes